Functions of neuronal adenosine receptors.
Endogenous adenosine in nervous tissue, a central link between energy metabolism and neuronal activity, varies according to behavioral state and (patho)physiological conditions, it may be the major sleep propensity substance. The functional consequences of activation of the four known adenosine receptors, A1, A2A, A2B and A3, are considered here. The mechanisms and electrophysiological actions, mainly those of the A1-receptor, have been extensively studied using in vitro brain-slice preparations. A1-receptor activation inhibits many neurons postsynaptically by inducing or modulating ionic currents and presynaptically by reducing transmitter release. A1-receptors are almost ubiquitous in the brain and affect various K+ (Ileak, IAHP), mixed cationic (Ih), or Ca2+ currents, through activation of Gi/o-proteins (coupled to ion channels, adenylyl cyclase or phospholipases). A2A-receptors are much more localized, their functional role in the striatum is only just emerging. A2B- and A3-receptors may be affected in pathophysiological events, their function is not yet clear. The cAMP-PKA signal cascade plays a central role in the regulation of both neural activity and energy metabolism. Under conditions of increased demand and decreased availability of energy (such as hypoxia, hypoglycemia and/or excessive neuronal activity), adenosine provides a powerful protective feedback mechanism. Interaction with adenosine metabolism is a promising target for therapeutic intervention in neurological and psychiatric diseases such as epilepsy, sleep, movement (parkinsonism or Huntington's disease) or psychiatric disorders (Alzheimer's disease, depression, schizophrenia or addiction).
Haas
H L
HL
Department of Neurophysiology, Heinrich Heine University, Düsseldorf, Germany. haas@uni-duesseldorf.de
Selbach
O
O
D000241:Adenosine / Q000502:physiology; D000818:Animals; D015220:Calcium Channels / Q000502:physiology; D004827:Epilepsy / Q000517:prevention & control; D006801:Humans; D009474:Neurons / Q000502:physiology*; D018377:Neurotransmitter Agents / Q000378:metabolism; D015221:Potassium Channels / Q000502:physiology; D018047:Receptors, Purinergic P1 / Q000502:physiology*; D012890:Sleep / Q000502:physiology
D015220:Calcium Channels; D018377:Neurotransmitter Agents; D015221:Potassium Channels; D018047:Receptors, Purinergic P1; D000241:Adenosine